Autophagy in 5-Fluorouracil Therapy in Gastrointestinal Cancer: Trends and Challenges
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: 5-Fluorouracil (5-FU)-based combination therapies are standard treatments for gastrointestinal cancer, where the modulation of autophagy is becoming increasingly important in offering effective treatment for patients in clinical practice. This review focuses on the role of autophagy in 5-FU-induced tumor suppression and cancer therapy in the digestive system. DATA SOURCES: All articles published in English from 1996 to date those assess the synergistic effect of autophagy and 5-FU in gastrointestinal cancer therapy were identified through a systematic online search by use of PubMed. The search terms were "autophagy" and "5-FU" and ("colorectal cancer" or "hepatocellular carcinoma" or "pancreatic adenocarcinoma" or "esophageal cancer" or "gallbladder carcinoma" or "gastric cancer"). STUDY SELECTION: Critical reviews on relevant aspects and original articles reporting in vitro and/or in vivo results regarding the efficiency of autophagy and 5-FU in gastrointestinal cancer therapy were reviewed, analyzed, and summarized. The exclusion criteria for the articles were as follows: (1) new materials (e.g., nanomaterial)-induced autophagy; (2) clinical and experimental studies on diagnostic and/or prognostic biomarkers in digestive system cancers; and (3) immunogenic cell death for anticancer chemotherapy. RESULTS: Most cell and animal experiments showed inhibition of autophagy by either pharmacological approaches or via genetic silencing of autophagy regulatory gene, resulting in a promotion of 5-FU-induced cancer cells death. Meanwhile, autophagy also plays a pro-death role and may mediate cell death in certain cancer cells where apoptosis is defective or difficult to induce. The dual role of autophagy complicates the use of autophagy inhibitor or inducer in cancer chemotherapy and generates inconsistency to an extent in clinic trials. CONCLUSION: Autophagy might be a therapeutic target that sensitizes the 5-FU treatment in gastrointestinal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
de la Cruz-Morcillo, M. A., Valero, M. L. L., Callejas-Valera, J. L., Arias-González, L., Melgar-Rojas, P., Galán-Moya, E. M., García-Gil, E., García-Cano, J., & Sánchez-Prieto, R. (2012) · Oncogene · doi:10.1038/onc.2011.321 · Cited by 117 · cited 2×
“HaCaT and HCT116 (colon cancer) SB203580 and RNAi (p38MAPK) MAP2K, MAPK kinase‐3, and MAPK kinase‐6 [35]”
BackgroundRetractedde Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“Colorectal cancer 5‐FU is a cornerstone in chemotherapy of advanced colorectal cancer;[39] improved combinations of 5‐FU with irinotecan; or oxaliplatin have progressively increased tumor response as well as the median survival time of patients with unresectable tumor.[40] Previous studies have demonstrated that inhib…”
BackgroundGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4
Scherz‐Shouval, R., Shvets, E., Fass, E., Shorer, H., Gil, L., & Elazar, Z. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601623 · Cited by 2,101 · cited 1×
“[75] Moreover, PKCI may regulate autophagy via intracellular ROS, a known autophagy inducer that promotes autophagy by inactivating the mTOR pathway[76] or inhibiting ATG4,[77] indicating that PKCI could be used as an autophagy inducer in killing esophageal cancer cells.”
BackgroundRole of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes
Shimizu, S., Kanaseki, T., Mizushima, N., Mizuta, T., Arakawa-Kobayashi, S., Thompson, C. B., & Tsujimoto, Y. (2004) · Nature Cell Biology · doi:10.1038/ncb1192 · Cited by 1,358
Autophagy-deficient mice develop multiple liver tumors
Takamura, A., Komatsu, M., Hara, T., Sakamoto, A., Kishi, C., Waguri, S., Eishi, Y., Hino, O., Tanaka, K., & Mizushima, N. (2011) · Genes & Development · doi:10.1101/gad.2016211 · Cited by 1,342
mTOR, translation initiation and cancer
Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209888 · Cited by 607 · cited 1×
“[62] Activation of PI3K results in sequential AKT and mTOR activation, ultimately suppressing autophagy.[63,64] Inhibition of autophagy results in enhanced apoptosis following treatment with PI3K inhibitors, in particular, dual‐targeted PI3K/mTOR inhibitors.”
BackgroundInduction of Autophagy during Extracellular Matrix Detachment Promotes Cell Survival
Fung, C., Lock, R., Gao, S., Salas, E., & Debnath, J. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-10-1092 · Cited by 558 · cited 1×
“This ability to cope with stress is also useful to cancer cells that disseminate and metastasize.[22] Hence, the paradox leads to a similar contradictory response of autophagy in tumor following anticancer treatments.”
BackgroundInhibition of Autophagy by 3-MA Enhances the Effect of 5-FU-Induced Apoptosis in Colon Cancer Cells
Li, J., Hou, N., Faried, A., Tsutsumi, S., Takeuchi, T., & Kuwano, H. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0260-0 · Cited by 291 · cited 3×
“HT‐29, colon 26 (colon cancer) 3‐MA (PI3K III) Bcl‐xL, cytochrome c/ caspase‐3/PARP pathway [34]”
BackgroundBoone, B. A., Bahary, N., Zureikat, A. H., Moser, A. J., Normolle, D. P., Wu, W.-C., Singhi, A. D., Bao, P., Bartlett, D. L., Liotta, L. A., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4566-4 · Cited by 234 · cited 1×
“[59] Furthermore, in phase I/II clinical trial, preoperative inhibition of autophagy with HCQ and gemcitabine in patients with pancreatic adenocarcinoma is safe, well‐tolerated, and effective.[60] However, a contradictive study showed that HCQ monotherapy achieved inconsistent autophagy inhibition and demonstrated neg…”
Background
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Ghafouri-Fard, S., Abak, A., Tondro Anamag, F., Shoorei, H., Fattahi, F., Javadinia, S. A., Basiri, A., & Taheri, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658636 · Cited by 193
Engineered exosomes with enhanced stability and delivery efficiency for glioblastoma therapy
Wang, Y., Huo, Y., Zhao, C., Liu, H., Shao, Y., Zhu, C., An, L., Chen, X., & Chen, Z. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.015 · Cited by 84
Metadata
- Authors
- Tang, J.-C., Feng, Y.-L., Liang, X., & Cai, X.-J.
- Venue
- Chinese Medical Journal
- Published
- 2016-02-20
- Volume
- 129
- Issue
- 4
- Pages
- 456-463
- ISSN
- 0366-6999 (ISSN-L)
- OpenAlex
- W2277721627
- Cited by
- 54
- References
- 12
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autophagy in 5-Fluorouracil Therapy in Gastrointestinal Cancer: Trends and Challenges. https://app.cochat.ai/papers/10.4103/0366-6999.176069
- The paper
- Tang, J.-C., Feng, Y.-L., Liang, X., & Cai, X.-J. (2016). Autophagy in 5-Fluorouracil Therapy in Gastrointestinal Cancer: Trends and Challenges. Chinese Medical Journal. https://doi.org/10.4103/0366-6999.176069
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.